NCT02824926 is a Phase 2 clinical trial of Dapaconazole in Tinea Pedis, sponsored by Gilberto De Nucci.

Who is sponsoring NCT02824926?

NCT02824926 is sponsored by Gilberto De Nucci.

What drugs are being tested in NCT02824926?

Interventions in NCT02824926: Dapaconazole, Ketoconazole.

What condition does NCT02824926 study?

NCT02824926 studies Tinea Pedis.

Is NCT02824926 still recruiting?

NCT02824926 is currently completed. Last updated 3 July 2016.

Last reviewed 2016-07-03 · How we verify

NCT02824926

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis

Completed Phase 2 Last updated 3 July 2016

What this trial tests

Phase 2 trial testing Dapaconazole in Tinea Pedis in 60 participants. Completed in 1 January 2015.

Timeline

1 July 2014

Primary endpoint
1 December 2014

1 January 2015

Quick facts

Lead sponsor	Gilberto De Nucci
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2014
Primary completion	1 December 2014
Estimated completion	1 January 2015

Drugs / interventions tested

Dapaconazole — full drug profile →
Ketoconazole (ketoconazole) — full drug profile →

Conditions studied

Tinea Pedis — all drugs for Tinea Pedis →

Sponsor

Gilberto De Nucci

Who can join

Adults 18 to 60, any sex, with Tinea Pedis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical cure of the lesion(s)
Time frame: 14 days
Assessment of presence or absence of lesion(s) by clinical examination
Mycological cure of the lesion(s)
Time frame: 14 days
Laboratory test for presence or absence of Tinea Pedis

Sponsor's own description

This is a non-inferiority, Phase II, open-label, randomized, parallel trial to evaluate efficacy and safety of the new intervention (Dapaconazole cream 2%) versus the active control (Ketoconazole cream 2%) in patients with Tinea Pedis. Study schedule comprises enrollment, treatment and follow-up visits. Treatment period is 14 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dapaconazole

Trials testing the same drug.

NCT03320486 — Non-inferiority Trial of Dapaconazole Versus Ketoconazole · Phase 3 · completed
NCT03359070 — Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris · Phase 2 · completed

Other recruiting trials for Tinea Pedis

Currently open trials in the same condition.

NCT07056660 — Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea Pedis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02824926 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilberto De Nucci
Last refreshed: 3 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02824926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing